Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Prostate-specific membrane antigen (PSMA) is a promising target for diagnosis and radioligand therapy (RLT) of prostate cancer. Two novel PSMA-targeting radionuclide therapy agents, [Lu]Lu-P17-087, and its albumin binder modified derivative, [Lu]Lu-P17-088, were evaluated in metastatic castration-resistant prostate cancer (mCRPC) patients. The primary endpoint was dosimetry evaluation, the second endpoint was radiation toxicity assessment (CTCAE 5.0) and PSA response (PCWG3).
Methods: Patients with PSMA-positive tumors were enrolled after [Ga]Ga-PSMA-11 PET/CT scan. Five mCRPC patients received [Lu]Lu-P17-087 and four other patients received [Lu]Lu-P17-088 (1.2 GBq/patient). Multiple whole body planar scintigraphy was performed at 1.5, 4, 24, 48, 72, 120 and 168 h after injection and one SPECT/CT imaging was performed at 24 h post-injection for each patient. Dosimetry evaluation was compared in both patient groups.
Results: Patients showed no major clinical side-effects under this low dose treatment. As expected [Lu]Lu-P17-088 with longer blood circulation (due to its albumin binding) exhibited higher effective doses than [Lu]Lu-P17-087 (0.151 ± 0.036 vs. 0.056 ± 0.019 mGy/MBq, P = 0.001). Similarly, red marrow received 0.119 ± 0.068 and 0.048 ± 0.020 mGy/MBq, while kidney doses were 0.119 ± 0.068 and 0.046 ± 0.022 mGy/MBq, respectively. [Lu]Lu-P17-087 demonstrated excellent tumor uptake and faster kinetics; while [Lu]Lu-P17-088 displayed a slower washout and higher average dose (7.75 ± 4.18 vs. 4.72 ± 2.29 mGy/MBq, P = 0.018). After administration of [Lu]Lu-P17-087 and [Lu]Lu-P17-088, 3/5 and 3/4 patients showed reducing PSA values, respectively.
Conclusion: [Lu]Lu-P17-088 and [Lu]Lu-P17-087 displayed different pharmacokinetics but excellent PSMA-targeting dose delivery in mCRPC patients. These two agents are promising RLT agents for personalized treatment of mCRPC. Further studies with increased dose and frequency of RLT are warranted to evaluate the potential therapeutic efficacy.
Trial Registration: Lu-P17-087/Lu-P17-088 in Patients with Metastatic Castration-resistant Prostate Cancer (NCT05603559, Registered at 25 October, 2022). URL OF REGISTRY: https://classic.
Clinicaltrials: gov/ct2/show/NCT05603559 .
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00259-024-06721-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing Workflow for Cone Beam Computed Tomography-Based Online Adaptive Radiation Therapy Toward Reduced Physician Involvement.
Adv Radiat Oncol
October 2025
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Radiation Oncology and Radiotherapy, Augustenburger Platz 1, 13353 Berlin, Germany.
Purpose: To evaluate the impact of an optimized online adaptive radiation therapy workflow on physician involvement.
Methods And Materials: Data from a prospective phase 2 trial involving 34 prostate cancer patients treated with cone beam computed tomography (CBCT)-based online adaptive radiation therapy (62 Gy in 20 fractions) were analyzed. Manual interventions were required for 2 steps in the workflow: radiation therapy technologist review and adjustment of automatically segmented organs, guiding target segmentation, so-called "influencer," while physicians reviewed and refined the targets.
SLC16A3 (MCT4) expression in tumor immunity and Metabolism: Insights from pan-cancer analysis.
Biochem Biophys Rep
June 2025
The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Background: SLC16A3, a highly expressed H + -coupled symporter, facilitates lactate transport via monocarboxylate transporters (MCTs), contributing to acidosis. Although SLC16A3 has been implicated in tumor development, its role in tumor immunity remains unclear.
Methods: A pan-cancer analysis was conducted using datasets from The Cancer Genome Atlas, Cancer Cell Line Encyclopedia, and Genotype-Tissue Expression projects.
Development of a novel risk model to predict CRPC progression following IMRT: Implications for tailoring treatment intensity.
BJUI Compass
September 2025
Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine Kyoto University Kyoto Kyoto Japan.
Objectives: To develop a novel risk score (RS) model to predict the probability of progression to castration-resistant prostate cancer (PCa) (CRPC) after intensity-modulated radiation therapy (IMRT) for patients with high- and very high-risk PCa according to the National Comprehensive Cancer Network (NCCN) risk classification, since accurate prediction of the clinical outcome of definitive radiation therapy for patients with high- and very high-risk PCa remains challenging due to its heterogeneity.
Materials And Methods: We conducted a retrospective review of 600 patients with high- and very high-risk PCa treated with IMRT at our institution. They were randomly divided into discovery (n = 300) and validation (n = 300) cohorts.
Optimizing dose rate to minimize delivery time in proton pencil beam dose-driven continuous scanning.
Med Phys
September 2025
Department of Radiation Oncology, Mayo Clinic in Florida, Jacksonville, Florida, USA.
Background: Dose-driven continuous scanning (DDCS) enhances the efficiency and precision of proton pencil beam delivery by reducing beam pauses inherent in discrete spot scanning (DSS). However, current DDCS optimization studies using traveling salesman problem (TSP) formulations often rely on fixed beam intensity and computationally expensive interpolation for move spot generation, limiting efficiency and methodological robustness.
Purpose: This study introduces a Break Spot-Guided (BSG) method, combined with two acceleration strategies-dose rate skipping and bounding-to optimize beam intensity while minimizing beam delivery time (BDT).
Prostate cancer characteristics in fathers and risk of early onset high-risk prostate cancer in sons.
Int J Cancer
September 2025
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
A family history of prostate cancer in first-degree relatives is an established risk factor for prostate cancer, but the specific associations between prostate cancer characteristics in fathers and the risk of high-risk prostate cancer in their sons remain unclear. We identified men in Prostate Cancer data Base Sweden whose fathers had been diagnosed with prostate cancer in 1998-2005. We compared the observed number of prostate cancer diagnoses in these men with the expected number in the Swedish male population, estimating standardized incidence ratios (SIR).
View Article and Find Full Text PDF